Related Experiment Video
Updated: Feb 11, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Effectiveness of alternative dose fingolimod for multiple sclerosis
Erin E Longbrake1, Daniel Kantor1, Siddharama Pawate1
1Yale University (EEL), New Haven, CT; Medical Partnership 4 MS (MP4MS) (DK), Coconut Creek, FL; Vanderbilt University (SP, MJB), Nashville, TN; University of Washington (GvG), Seattle; Washington University (SC, AHC, BJP), St. Louis, MO; MS Center of Tidewater (MR), Norfolk, VA; Nehme & Therese Tohme MS Center (SJK, BY, MZ), Beirut, Lebanon; RWJ Barnabas Health (SR-G, IK), West Orange, NJ; C/Fuentes Claras 1 (AC-R), Avila, Spain; MS Center of Northeastern NY (KE), Latham; Elliot Lewis Center for MS Care (EL), Wellesley, MA; Spectrum Health Medical Group (DV), Grand Rapids, MI; University of Alabama (WM), Birmingham; University of Southern California (RB), Los Angeles; and NYU Langone Health (LG, TEB, IK), New York, NY.
Alternate fingolimod dosing maintains similar disease control as daily dosing for relapsing multiple sclerosis (MS) patients experiencing adverse events. This strategy supports managing MS with profound lymphopenia or other side effects.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Fingolimod is an oral medication for relapsing multiple sclerosis (MS).
- Clinicians may use less frequent dosing due to adverse events like lymphopenia.
- Limited data exist on alternate fingolimod dosing effectiveness.
Purpose of the Study:
- To evaluate the effectiveness of alternate-dose fingolimod in MS patients.
- To compare clinical and radiologic outcomes between daily and alternate fingolimod dosing.
Main Methods:
- Multicenter, retrospective, observational study.
- 170 MS patients on alternate fingolimod doses for ≥1 month.
- Comparison of outcomes during daily vs. alternate dosing.
Main Results:
- Common reasons for alternate dosing: lymphopenia (77%), liver abnormalities (9%), infections (7%).
- Similar disease activity: annualized relapse rate (0.1 vs. 0.2), contrast-enhancing lesions (7.6% vs. 9.4%).
- Prior contrast-enhancing lesions predicted breakthrough disease on alternate dosing (OR 11.4, p < 0.001).
Conclusions:
- Alternate fingolimod dosing is a viable strategy for MS patients with adverse events.
- Supports managing patients with profound lymphopenia or other side effects.
- Class IV evidence suggests similar disease activity compared to daily dosing.
Related Concept Videos
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

